BG107208A - Аморфна тораземидна модификация - Google Patents

Аморфна тораземидна модификация

Info

Publication number
BG107208A
BG107208A BG107208A BG10720802A BG107208A BG 107208 A BG107208 A BG 107208A BG 107208 A BG107208 A BG 107208A BG 10720802 A BG10720802 A BG 10720802A BG 107208 A BG107208 A BG 107208A
Authority
BG
Bulgaria
Prior art keywords
amorphic
torasemide
torasemide modification
modification
preparation
Prior art date
Application number
BG107208A
Other languages
Bulgarian (bg)
English (en)
Inventor
Darko Filic
Miljenko Dumic
Bozena Klepic
Aleksandar Danilovski
Marijan Tudja
Original Assignee
Pliva, Farmaceutska Industrija, Dionicko Drustvo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva, Farmaceutska Industrija, Dionicko Drustvo filed Critical Pliva, Farmaceutska Industrija, Dionicko Drustvo
Publication of BG107208A publication Critical patent/BG107208A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
BG107208A 2000-03-20 2002-10-21 Аморфна тораземидна модификация BG107208A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR20000162A HRP20000162B1 (en) 2000-03-20 2000-03-20 Amorphous torasemide modification
PCT/HR2000/000011 WO2001070694A1 (en) 2000-03-20 2000-05-02 Amorphous torasemide modification

Publications (1)

Publication Number Publication Date
BG107208A true BG107208A (bg) 2003-07-31

Family

ID=10947070

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107208A BG107208A (bg) 2000-03-20 2002-10-21 Аморфна тораземидна модификация

Country Status (29)

Country Link
US (1) US6767917B1 (es)
EP (1) EP1272470B1 (es)
JP (1) JP2003528083A (es)
KR (1) KR20020093847A (es)
CN (1) CN1211368C (es)
AR (1) AR023788A1 (es)
AT (1) ATE256662T1 (es)
AU (1) AU2000241348A1 (es)
BG (1) BG107208A (es)
BR (1) BR0017175A (es)
CA (1) CA2401908A1 (es)
CZ (1) CZ20023436A3 (es)
DE (1) DE60007360T2 (es)
EA (1) EA004950B1 (es)
EE (1) EE200200534A (es)
ES (1) ES2213006T3 (es)
GE (1) GEP20043300B (es)
HR (1) HRP20000162B1 (es)
HU (1) HUP0300596A3 (es)
IL (1) IL151801A0 (es)
IS (1) IS6551A (es)
MX (1) MXPA02009210A (es)
NO (1) NO20024464L (es)
PL (1) PL357154A1 (es)
PT (1) PT1272470E (es)
SK (1) SK15092002A3 (es)
WO (1) WO2001070694A1 (es)
YU (1) YU70502A (es)
ZA (1) ZA200208309B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527319A (ja) * 1999-08-11 2003-09-16 テバ ファーマシューティカル インダストリーズ リミティド トルセミド多形体
IN192178B (es) 2001-08-03 2004-03-06 Ranbaxy Lab
US20070238740A1 (en) 2003-08-28 2007-10-11 Nitromed, Inc. Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
AU2006216665A1 (en) 2005-02-24 2006-08-31 Nicox S.A. Nitric oxide enhancing diuretic compounds, compositions and methods of use
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
DK0812320T3 (da) 1995-02-22 2003-04-14 Aventis Pharma Ltd Amorft piretanid, polymorfe former deraf, fremgangsmåde til fremstilling deraf og deres anvendelse
IN182496B (es) 1996-02-20 1999-04-17 Reddy Research Foundation
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
JP2003527319A (ja) 1999-08-11 2003-09-16 テバ ファーマシューティカル インダストリーズ リミティド トルセミド多形体

Also Published As

Publication number Publication date
CN1452613A (zh) 2003-10-29
PT1272470E (pt) 2004-05-31
HRP20000162B1 (en) 2004-06-30
HRP20000162A2 (en) 2001-12-31
EE200200534A (et) 2004-04-15
DE60007360T2 (de) 2004-10-07
ZA200208309B (en) 2003-10-15
CA2401908A1 (en) 2001-09-27
EA004950B1 (ru) 2004-10-28
PL357154A1 (en) 2004-07-12
JP2003528083A (ja) 2003-09-24
WO2001070694A1 (en) 2001-09-27
US6767917B1 (en) 2004-07-27
EP1272470A1 (en) 2003-01-08
NO20024464L (no) 2002-09-20
CZ20023436A3 (cs) 2003-03-12
YU70502A (sh) 2006-01-16
EP1272470B1 (en) 2003-12-17
WO2001070694A8 (en) 2002-03-21
AU2000241348A1 (en) 2001-10-03
EA200201003A1 (ru) 2003-02-27
HUP0300596A2 (hu) 2003-07-28
IS6551A (is) 2002-09-17
AR023788A1 (es) 2002-09-04
BR0017175A (pt) 2002-12-10
HUP0300596A3 (en) 2005-08-29
CN1211368C (zh) 2005-07-20
GEP20043300B (en) 2004-02-10
ES2213006T3 (es) 2004-08-16
NO20024464D0 (no) 2002-09-18
SK15092002A3 (sk) 2003-05-02
ATE256662T1 (de) 2004-01-15
IL151801A0 (en) 2003-04-10
DE60007360D1 (de) 2004-01-29
MXPA02009210A (es) 2004-09-06
KR20020093847A (ko) 2002-12-16

Similar Documents

Publication Publication Date Title
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
WO2001032632A3 (en) Pharmaceutically active 4-substituted pyrimidine derivatives
EE04911B1 (et) Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
JO2371B1 (en) 4-phenyl-pyridine derivatives
EE200200486A (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, uued derivaadid ja nende valmistamismeetodid
ZA992951B (en) N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders.
GB0003154D0 (en) Novel compounds
BR0108395A (pt) Derivados de pirrolopirimidinona, processos de preparação e uso
UY27368A1 (es) Nuevos compuestos
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
SE0102036D0 (sv) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
NO963850L (no) Heterosykliske forbindelser, deres fremstilling og anvendelse
ATE291908T1 (de) Ibuprofen-wirkstoffzubereitung
NO20020282D0 (no) Nytt difenylpiperidinderivat
BG107208A (bg) Аморфна тораземидна модификация
SE0102440D0 (sv) New compound
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
AP2002002679A0 (en) Novel polymorph V of torasemide.
HUP0203338A2 (hu) Integrin receptor ligandumok
YU35303A (sh) Preparati n-(1-metiletilaminokarbonil)-4-(3-metilfenil-amino)-3-piridinsulfonamida i cikličnih oligosaharida
MXPA02012015A (es) Ligandos de receptores para integrinas.
ATE286395T1 (de) Antithrombotische mittel
AR022718A1 (es) 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-olessustituidos con n-(5-fenil-tetrahidrofuranil)metilo y n-(6-fenil-tetrahidropiranil)metilo;procedimientos para prepararlos y su empleo como composiciones farmaceuticas.
BR0115042A (pt) Ligandos de receptores de aminoalquilpirrolidina serotonina e composições, seus usos farmacêuticos, e processos para a sua sìntese